We are the MOGLYNET-PhD programme in drug discovery and development.
The Horizon 2020 MSCA joint doctoral project MOGLYNET (“Modulation of glycolytic flux as a new approach for treatment of atherosclerosis and plaque stabilization: a multidisciplinary study”) is run by a Consortium of Universities in cooperation with Industries and Associations operating in the Pharma sector with the aim to offer an innovative PhD level training in Drug Discovery and Development to 12 Early Stage Researchers
